The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging
Authors Zhu YY, Chen C, Li JJ, Sun SR
Received 12 December 2017
Accepted for publication 9 April 2018
Published 28 June 2018 Volume 2018:13 Pages 3795—3803
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Linlin Sun
Yong-yun Zhu,1 Chuang Chen,2 Juan-Juan Li,2 Sheng-Rong Sun2
1Department of Thyroid and Breast Surgery, Wuhu Second People’s Hospital, Wuhu, Anhui 24100, People’s Republic of China; 2Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People’s Republic of China
Objective: Breast cancer is the most common malignancy and one of the main causes of death in women. Luminal B (HER2-) breast cancer subtype has been proposed since the 2011 St Gallon consensus. The hormone receptor status in this type of breast cancer is positive; thus, endocrine therapy was performed in all cases, but the treatment was not satisfactory, and a significant number of cases received very little benefit from chemotherapy. Furthermore, there is no effective treatment target for this subtype. Luminal B (HER2-) breast cancer subtype has been proposed since the 2011 St Gallon consensus. Therefore, the study of the key molecules in the microenvironment of breast cancer can help to reveal the biological characteristics.
Patients and methods: Luminal B (HER2-) breast cancer is a subtype with higher heterogeneity and poorer prognosis than luminal A. It is known that the development of cancer cells is an active process, and this process needs microenvironment cytokines, including chemokine (C–C motif) ligand 5 (CCL5) and collagen IV. Therefore, CCL5 and collagen IV were imaged and detected by quantum dot, and the CCL5/collagen IV ratio was calculated to investigate the prognostic value of the CCL5/collagen IV ratio in luminal B (HER2-).
Results: Quantitative determination showed a statistically significant negative correlation between CCL5 and collagen IV. The 5-year disease-free survival (5-DFS) of the high and low CCL5/collagen IV ratio subgroups was significantly different. The CCL5/collagen IV ratio had a greater prognostic value for 5-DFS. The CCL5/collagen IV ratio was an independent prognostic indicator.
Conclusion: Our findings revealed the effective integration of tumor CCL5 and collagen IV, and a new method for predicting the prognosis of luminal B (HER2-) has been developed.
Keywords: quantum dot, luminal B, HER2-, chemokine, C–C motif, ligand 5, collagen IV
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]